NRG BR004

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

NCT#03199885

BR004 re-opened to accrual, effective August 3, 2021.